Get startedLog in
    Picture of SynAct Pharma AB logo

    SYNACT — SynAct Pharma AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Synact Pharma Receives EU Trial Approval For Study With Resomelagon

    Picture of SynAct Pharma AB logoSynAct Pharma AB
    27/11/2024 06:34
    Nov 27 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * SYNACT PHARMA RECEIVES EU TRIAL APPROVAL FOR THE PHASE 2B
ADVANCE STUDY WITH RESOMELAGON (AP1189)

Source text:  ID:nMFNyVdgT 
Further company coverage:  SYNACT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on SynAct Pharma AB

    See all news